STAGE IV NON-SMALL CELL LUNG CANCER
Clinical trials for STAGE IV NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new STAGE IV NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for STAGE IV NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink Hard-to-Treat lung tumors
Disease control OngoingThis early-phase study tests a combination of two drugs, ceritinib and docetaxel, in people with advanced non-small cell lung cancer that does not have certain gene changes (ALK-negative, EGFR wild-type). The main goal is to find the safest dose and see if the combination can shr…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 17, 2026 02:21 UTC
-
CRISPR lung cancer trial pulled before it even started
Disease control TerminatedThis trial aimed to test a new treatment for people with metastatic non-small cell lung cancer. Doctors would take immune cells from a patient's tumor, use CRISPR gene editing to make them stronger, and then put them back into the patient. The goal was to see if these edited cell…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Intima Bioscience, Inc. • Aim: Disease control
Last updated May 17, 2026 02:18 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called sEphB4-HSA alongside standard chemotherapy in people with advanced or metastatic solid tumors (like head and neck, pancreatic, lung, and gallbladder cancers). The main goals are to find the best dose and check for side effects. About…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Lung cancer combo fails to boost survival in key trial
Disease control OngoingThis study tested whether adding cetuximab to the standard drug afatinib helps people with advanced EGFR-mutant lung cancer live longer. 174 newly diagnosed patients received either the combination or afatinib alone. The main goal was to see if more patients were alive after two …
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for advanced lung cancer: adding targeted treatment may extend life
Disease control OngoingThis study tests whether adding local treatments like radiation or surgery to standard maintenance chemotherapy helps people with stage IV non-small cell lung cancer live longer without the disease getting worse. About 218 participants are randomly assigned to receive either main…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Blood test could predict cancer treatment success in large global study
Knowledge-focused OngoingThis study is collecting blood samples from 10,000 people with advanced lung cancer or melanoma to build a computer algorithm that predicts how well their treatment will work. Researchers analyze proteins in the blood before and during therapy to see if they can forecast outcomes…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Sponsor: OncoHost Ltd. • Aim: Knowledge-focused
Last updated Apr 26, 2026 19:35 UTC